Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Larazotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 5/20 | 0.41 |
| ▸ | NPY4R | P50391 | 5/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.41 |
| ▸ | NPY1R | P25929 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | TFPI | P10646 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Larazotide SCHEMBL23668121 | 0.98 | CAPN1 (0.43) | CAPN1OPRD1STAT3NTSR1NPY2R | |
| Larazotide SCHEMBL23668120 | 0.98 | CAPN1 (0.43) | CAPN1OPRD1STAT3NTSR1NPY2R | |
| Larazotide SCHEMBL28795844 | 0.98 | CAPN1 (0.43) | CAPN1OPRD1STAT3NTSR1NPY2R | |
| SCHEMBL30286103 | 0.95 | CAPN1 (0.43) | CAPN1OPRD1STAT3NTSR1NPY2R | |
| SCHEMBL29568037 | 0.89 | CAPN1 (0.42) | CAPN1OPRD1STAT3NTSR1 | |
| SCHEMBL30197449 | 0.88 | CAPN1 (0.44) | CAPN1STAT3NTSR1NPY2RNPY4R | |
| SCHEMBL30539771 | 0.85 | CTSD (0.42) | CAPN1STAT3NTSR1CTSDBACE1 | |
| SCHEMBL29566935 | 0.85 | OPRD1 (0.41) | CAPN1OPRD1NTSR1KEAP1 | |
| SCHEMBL29567365 | 0.85 | NTSR1 (0.40) | CAPN1OPRD1STAT3NTSR1KEAP1 | |
| SCHEMBL29567235 | 0.85 | NTSR1 (0.40) | CAPN1OPRD1STAT3NTSR1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-12414979-B2 | Compositions and methods for treating Sjogren's syndrome | INTERLUDE BIOPHARMA CO. (US) | 2025-09-16 | — | — | US | claimed |
| WO-2024222890-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-31 | — | — | WO | claimed |
| EP-4326304-A1 | ZONULIN ANTAGONISTS FOR THE TREATMENT OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) AND ADULTS (MIS-A) | Ebris S.r.l. (IT) | 2024-02-28 | — | — | EP | claimed |
| WO-2024030909-A1 | BIOMARKERS OF AMINO ACID COMPOSITION TREATMENT RESPONSE IN LONG COVID | AXCELLA HEALTH INC. (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2024026307-A1 | BIOMARKER FOR LONG COVID AND FATIGUE | AXCELLA HEALTH INC. (US) | 2024-02-01 | — | — | WO | claimed |
| US-20240011991-A1 | COMPOSITIONS AND METHODS FOR PREDICTING RISK OF MODERATE TO SEVERE COVID-19 DISEASE | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-01-11 | — | — | US | claimed |
| WO-2022224059-A1 | ZONULIN ANTAGONISTS FOR THE TREATMENT OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) AND ADULTS (MIS-A) | EBRIS S.R,L, (IT) | 2022-10-27 | — | — | WO | claimed |
| WO-2022103971-A1 | COMPOSITIONS AND METHODS FOR PREDICTING RISK OF MODERATE TO SEVERE COVID-19 DISEASE | THE WISTAR INSTITUE OF ANATOMY AND BIOLOGY (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220047668-A1 | COMPOSITIONS AND METHODS FOR TREATING SJOGREN'S SYNDROME | INTERLUDE BIOPHARMA CO. | 2022-02-17 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12630839-B2 | Compositions for the treatment of Fabry disease | SANGAMO THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-20220047668-A1 | COMPOSITIONS AND METHODS FOR TREATING SJOGREN'S SYNDROME | INTERLUDE BIOPHARMA CO. | 2022-02-17 | — | — | US | disclosed |
| US-11248028-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220031681-A1 | Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones | AMICUS THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | CAPN1 2722/4885OPRD1 905/4885STAT3 1976/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | CAPN1 2887/4885OPRD1 457/4885STAT3 47/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | CAPN1 2602/4885OPRD1 520/4885STAT3 25/4885 |
| US-12630839-B2 | Compositions for the treatment of Fabry disease | APOB, HBB, GLA | CAPN1 2059/4885OPRD1 3759/4885STAT3 742/4885 |
| US-20220047668-A1 | COMPOSITIONS AND METHODS FOR TREATING SJOGREN'S SYNDROME | SSB, PDE12, PDE3A | CAPN1 2953/4885OPRD1 4501/4885STAT3 2634/4885 |
| US-12414979-B2 | Compositions and methods for treating Sjogren's syndrome | SSB, PDE12, PDE3A | CAPN1 2953/4885OPRD1 4501/4885STAT3 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.